Boehringer Ingelheim Lands Positive Results in Lung Disease TrialClinical Trials, Connective Tissue, Data, European Medicines Agency, FDA, Idiopathic Pulmonary Fibrosis, merican Thoracic Society (ATS) International Conference, Priority Review Status, R&D, Researchers, Scleroderma, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), The New England Journal of Medicine (NEJM)Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD. Read more May 21, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-05-21 12:29:042019-05-21 13:01:42Boehringer Ingelheim Lands Positive Results in Lung Disease Trial